Advances in the Management of Renal Cell Carcinoma: Addressing Gaps and Elevating Care for Patients

Driven by new insights into tumor biology and immune response, the therapeutic landscape for advanced renal cell carcinoma (RCC) continues to rapidly expand. As immunotherapy and VEGF-targeted combinations become central to RCC management, oncology teams must balance an increasing number of treatment options with growing clinical complexity. Clinicians caring for patients with early-stage or advanced RCC need clear, up-to-date guidelines to confidently interpret emerging evidence, tailor treatment to individual goals and risk profiles, and deliver consistent, high-quality care.

In this CE Concepts recorded Grand Rounds, expert faculty will discuss the latest clinical trial data and guideline recommendations shaping contemporary RCC care. Through a case-based discussion format, faculty will demonstrate how to personalize treatment plans that reflect patient-specific factors and evolving standards of care. Faculty will also share practical approaches to anticipating and managing adverse events, thus equipping multidisciplinary teams to deliver safe, effective, and patient-centered RCC care.

At the conclusion of this activity, learners will be able to better:

• Evaluate the latest clinical data and consensus guideline recommendations on systemic treatment approaches for patients with operable, advanced, or metastatic renal cell carcinoma (RCC)
• Develop personalized treatment plans for patients with metastatic RCC (mRCC) that integrate patient-specific factors, risk assessment, and guideline recommendations in community oncology settings
• Integrate strategies to proactively manage adverse events (AEs) across multidisciplinary care settings for patients with advanced or mRCC

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Community medical oncologists, genitourinary oncologists, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, and other clinicians who provide care to individuals with renal cancer

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Powles reports the following financial relationships:

Advisory Board: Astellas Pharma Inc.; AstraZeneca; Bristol Myers Squibb Company; Eisai Co. Ltd.; Exelixis Inc.; Incyte; Ipsen Pharma; Johnson & Johnson; Mashup Ltd.; Merck Serono Ltd.; MSD; Novartis AG; Pfizer Inc.; Roche; and Seattle Genetics, Inc./Seagen Inc.

Grants: Astellas Pharma Inc.; AstraZeneca; Bristol Myers Squibb Company; Eisai Co. Ltd.; Exelixis Inc.; Ipsen Pharma; Johnson & Johnson; Merck Serono Ltd.; MSD; Novartis AG; Pfizer Inc.; Roche; and Seattle Genetics, Inc./Seagen Inc.

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Nichole Lainhart (Planning Committee)
Taylor Wallace, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.